Zoetis Inc. $ZTS Shares Sold by WASHINGTON TRUST Co

WASHINGTON TRUST Co trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 24.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 55,184 shares of the company’s stock after selling 17,727 shares during the quarter. WASHINGTON TRUST Co’s holdings in Zoetis were worth $6,943,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nordea Investment Management AB boosted its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. Seilern Investment Management Ltd boosted its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after purchasing an additional 261,155 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after purchasing an additional 935,432 shares during the period. Prudential PLC boosted its stake in shares of Zoetis by 17.7% in the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock valued at $28,950,000 after purchasing an additional 29,702 shares during the period. Finally, AE Wealth Management LLC boosted its stake in shares of Zoetis by 71.3% in the fourth quarter. AE Wealth Management LLC now owns 144,531 shares of the company’s stock valued at $18,185,000 after purchasing an additional 60,167 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. Morgan Stanley restated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $133.92.

Insiders Place Their Bets

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

Zoetis Trading Down 0.6%

ZTS opened at $77.81 on Friday. The stock has a market capitalization of $32.62 billion, a PE ratio of 12.90, a P/E/G ratio of 1.28 and a beta of 0.87. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $172.23. The firm’s fifty day moving average price is $104.29 and its 200 day moving average price is $117.03. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.